VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE
Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate...
Gespeichert in:
Veröffentlicht in: | Journal of neuroimmunology 2009-04, Vol.209 (1), p.6-15 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 15 |
---|---|
container_issue | 1 |
container_start_page | 6 |
container_title | Journal of neuroimmunology |
container_volume | 209 |
creator | Roscoe, W.A Welsh, M.E Carter, D.E Karlik, S.J |
description | Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increas |
doi_str_mv | 10.1016/j.jneuroim.2009.01.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67145673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0165572809000101</els_id><sourcerecordid>67145673</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</originalsourceid><addsrcrecordid>eNqFkc1O3DAQxy1UBMvHK6CcUHtIGH8muSAQWpaqIA60vVpeZwIO2WRrJ5W49R14Q54Eb3cREhcO1v_g38zYvyHkiEJGgaqTJms6HH3vFhkDKDOgWYwtMqFFztJCMPqFTCIoU5mzYpfshdAAUMlFuUN2ack4FwWfkB-_p7PLxHRVPPeuv8cOgwuJ6xJjxwH_39gH33fOJje3s69cvvx7lvJbssTl4CqMZDVarJLp-fSAbNemDXi4yX3y63L68-Iqvb6dfb84v05tfNaQKgplbuq8Li0IKxSARVnkdWGkKKRgJZtzBgp5YSo6V0JwyEtVYyVULWBu-D45Xvdd-v7PiGHQCxcstq3psB-DVjkVUuU8gmoNWt-H4LHWS-8Wxj9pCnqlUTf6TaNeadRAdYxYeLSZMM4XWL2XbbxF4GwNYPznX4deB-uwiyKcRzvoqnefzzj90MK2Lmo27SM-YWj60XfRoqY6MA36brXM1S6hhLhIoPwVfdmZpQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67145673</pqid></control><display><type>article</type><title>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Roscoe, W.A ; Welsh, M.E ; Carter, D.E ; Karlik, S.J</creator><creatorcontrib>Roscoe, W.A ; Welsh, M.E ; Carter, D.E ; Karlik, S.J</creatorcontrib><description><![CDATA[Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increase in several angiogenic RNA transcripts, six of which were verified by RT-PCR, alanyl aminopeptidase, caspase 8, Hif1a, MMP-19, plasminogen activator inhibitor, and thrombospondin1.]]></description><identifier>ISSN: 0165-5728</identifier><identifier>EISSN: 1872-8421</identifier><identifier>DOI: 10.1016/j.jneuroim.2009.01.009</identifier><identifier>PMID: 19233483</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Alanyl aminopeptidase ; Allergy and Immunology ; Angiogenesis ; Angiogenesis Inhibitors - pharmacology ; Angiogenesis Inhibitors - therapeutic use ; Angiogenic Proteins - genetics ; Animals ; Blood Vessels - drug effects ; Blood Vessels - metabolism ; Blood Vessels - pathology ; Caspase 8 ; Disease Models, Animal ; EAE ; Encephalomyelitis, Autoimmune, Experimental - drug therapy ; Encephalomyelitis, Autoimmune, Experimental - immunology ; Encephalomyelitis, Autoimmune, Experimental - metabolism ; Female ; Glycoproteins ; Hif1a ; Indoles - pharmacology ; Indoles - therapeutic use ; Laminin ; Laminin - drug effects ; Laminin - metabolism ; Mice ; Mice, Inbred C57BL ; MMP-19 ; Multiple sclerosis ; Myelin Sheath - drug effects ; Myelin Sheath - immunology ; Myelin Sheath - pathology ; Myelin-Oligodendrocyte Glycoprotein ; Neovascularization, Pathologic - drug therapy ; Neovascularization, Pathologic - metabolism ; Neovascularization, Pathologic - physiopathology ; Neurology ; Peptide Fragments ; Plasminogen activator inhibitor ; Pyrroles - pharmacology ; Pyrroles - therapeutic use ; Remyelination ; RNA, Messenger - drug effects ; RNA, Messenger - metabolism ; Spinal Cord - drug effects ; Spinal Cord - metabolism ; Spinal Cord - pathology ; SU5416 ; Thrombospondin ; Up-Regulation - drug effects ; Up-Regulation - physiology ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vascular Endothelial Growth Factor A - metabolism ; Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors ; Vascular Endothelial Growth Factor Receptor-2 - metabolism ; VEGF ; Wallerian Degeneration - chemically induced ; Wallerian Degeneration - pathology ; Wallerian Degeneration - physiopathology</subject><ispartof>Journal of neuroimmunology, 2009-04, Vol.209 (1), p.6-15</ispartof><rights>2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</citedby><cites>FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165572809000101$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19233483$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roscoe, W.A</creatorcontrib><creatorcontrib>Welsh, M.E</creatorcontrib><creatorcontrib>Carter, D.E</creatorcontrib><creatorcontrib>Karlik, S.J</creatorcontrib><title>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</title><title>Journal of neuroimmunology</title><addtitle>J Neuroimmunol</addtitle><description><![CDATA[Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increase in several angiogenic RNA transcripts, six of which were verified by RT-PCR, alanyl aminopeptidase, caspase 8, Hif1a, MMP-19, plasminogen activator inhibitor, and thrombospondin1.]]></description><subject>Alanyl aminopeptidase</subject><subject>Allergy and Immunology</subject><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - pharmacology</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Angiogenic Proteins - genetics</subject><subject>Animals</subject><subject>Blood Vessels - drug effects</subject><subject>Blood Vessels - metabolism</subject><subject>Blood Vessels - pathology</subject><subject>Caspase 8</subject><subject>Disease Models, Animal</subject><subject>EAE</subject><subject>Encephalomyelitis, Autoimmune, Experimental - drug therapy</subject><subject>Encephalomyelitis, Autoimmune, Experimental - immunology</subject><subject>Encephalomyelitis, Autoimmune, Experimental - metabolism</subject><subject>Female</subject><subject>Glycoproteins</subject><subject>Hif1a</subject><subject>Indoles - pharmacology</subject><subject>Indoles - therapeutic use</subject><subject>Laminin</subject><subject>Laminin - drug effects</subject><subject>Laminin - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>MMP-19</subject><subject>Multiple sclerosis</subject><subject>Myelin Sheath - drug effects</subject><subject>Myelin Sheath - immunology</subject><subject>Myelin Sheath - pathology</subject><subject>Myelin-Oligodendrocyte Glycoprotein</subject><subject>Neovascularization, Pathologic - drug therapy</subject><subject>Neovascularization, Pathologic - metabolism</subject><subject>Neovascularization, Pathologic - physiopathology</subject><subject>Neurology</subject><subject>Peptide Fragments</subject><subject>Plasminogen activator inhibitor</subject><subject>Pyrroles - pharmacology</subject><subject>Pyrroles - therapeutic use</subject><subject>Remyelination</subject><subject>RNA, Messenger - drug effects</subject><subject>RNA, Messenger - metabolism</subject><subject>Spinal Cord - drug effects</subject><subject>Spinal Cord - metabolism</subject><subject>Spinal Cord - pathology</subject><subject>SU5416</subject><subject>Thrombospondin</subject><subject>Up-Regulation - drug effects</subject><subject>Up-Regulation - physiology</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors</subject><subject>Vascular Endothelial Growth Factor Receptor-2 - metabolism</subject><subject>VEGF</subject><subject>Wallerian Degeneration - chemically induced</subject><subject>Wallerian Degeneration - pathology</subject><subject>Wallerian Degeneration - physiopathology</subject><issn>0165-5728</issn><issn>1872-8421</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1O3DAQxy1UBMvHK6CcUHtIGH8muSAQWpaqIA60vVpeZwIO2WRrJ5W49R14Q54Eb3cREhcO1v_g38zYvyHkiEJGgaqTJms6HH3vFhkDKDOgWYwtMqFFztJCMPqFTCIoU5mzYpfshdAAUMlFuUN2ack4FwWfkB-_p7PLxHRVPPeuv8cOgwuJ6xJjxwH_39gH33fOJje3s69cvvx7lvJbssTl4CqMZDVarJLp-fSAbNemDXi4yX3y63L68-Iqvb6dfb84v05tfNaQKgplbuq8Li0IKxSARVnkdWGkKKRgJZtzBgp5YSo6V0JwyEtVYyVULWBu-D45Xvdd-v7PiGHQCxcstq3psB-DVjkVUuU8gmoNWt-H4LHWS-8Wxj9pCnqlUTf6TaNeadRAdYxYeLSZMM4XWL2XbbxF4GwNYPznX4deB-uwiyKcRzvoqnefzzj90MK2Lmo27SM-YWj60XfRoqY6MA36brXM1S6hhLhIoPwVfdmZpQ</recordid><startdate>20090430</startdate><enddate>20090430</enddate><creator>Roscoe, W.A</creator><creator>Welsh, M.E</creator><creator>Carter, D.E</creator><creator>Karlik, S.J</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090430</creationdate><title>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</title><author>Roscoe, W.A ; Welsh, M.E ; Carter, D.E ; Karlik, S.J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-61097af7f9c04c4600ce587f8a54854292b3206e38ad1b64430796fed46f40ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Alanyl aminopeptidase</topic><topic>Allergy and Immunology</topic><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - pharmacology</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Angiogenic Proteins - genetics</topic><topic>Animals</topic><topic>Blood Vessels - drug effects</topic><topic>Blood Vessels - metabolism</topic><topic>Blood Vessels - pathology</topic><topic>Caspase 8</topic><topic>Disease Models, Animal</topic><topic>EAE</topic><topic>Encephalomyelitis, Autoimmune, Experimental - drug therapy</topic><topic>Encephalomyelitis, Autoimmune, Experimental - immunology</topic><topic>Encephalomyelitis, Autoimmune, Experimental - metabolism</topic><topic>Female</topic><topic>Glycoproteins</topic><topic>Hif1a</topic><topic>Indoles - pharmacology</topic><topic>Indoles - therapeutic use</topic><topic>Laminin</topic><topic>Laminin - drug effects</topic><topic>Laminin - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>MMP-19</topic><topic>Multiple sclerosis</topic><topic>Myelin Sheath - drug effects</topic><topic>Myelin Sheath - immunology</topic><topic>Myelin Sheath - pathology</topic><topic>Myelin-Oligodendrocyte Glycoprotein</topic><topic>Neovascularization, Pathologic - drug therapy</topic><topic>Neovascularization, Pathologic - metabolism</topic><topic>Neovascularization, Pathologic - physiopathology</topic><topic>Neurology</topic><topic>Peptide Fragments</topic><topic>Plasminogen activator inhibitor</topic><topic>Pyrroles - pharmacology</topic><topic>Pyrroles - therapeutic use</topic><topic>Remyelination</topic><topic>RNA, Messenger - drug effects</topic><topic>RNA, Messenger - metabolism</topic><topic>Spinal Cord - drug effects</topic><topic>Spinal Cord - metabolism</topic><topic>Spinal Cord - pathology</topic><topic>SU5416</topic><topic>Thrombospondin</topic><topic>Up-Regulation - drug effects</topic><topic>Up-Regulation - physiology</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors</topic><topic>Vascular Endothelial Growth Factor Receptor-2 - metabolism</topic><topic>VEGF</topic><topic>Wallerian Degeneration - chemically induced</topic><topic>Wallerian Degeneration - pathology</topic><topic>Wallerian Degeneration - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roscoe, W.A</creatorcontrib><creatorcontrib>Welsh, M.E</creatorcontrib><creatorcontrib>Carter, D.E</creatorcontrib><creatorcontrib>Karlik, S.J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuroimmunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roscoe, W.A</au><au>Welsh, M.E</au><au>Carter, D.E</au><au>Karlik, S.J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE</atitle><jtitle>Journal of neuroimmunology</jtitle><addtitle>J Neuroimmunol</addtitle><date>2009-04-30</date><risdate>2009</risdate><volume>209</volume><issue>1</issue><spage>6</spage><epage>15</epage><pages>6-15</pages><issn>0165-5728</issn><eissn>1872-8421</eissn><abstract><![CDATA[Abstract An increased expression of vascular endothelial growth factor (VEGF) is associated with demyelinated lesions in both multiple sclerosis (MS) and its model (EAE), implicating changes in vasculature as a potential component of CNS plaque formation. The purpose of this study was to investigate the vascular changes in acute and chronic EAE in C57BL/6 mice induced with myelin oligodendrocyte glycoprotein (MOG35–55 ) peptide. We investigated the functional contribution of VEGF to acute and chronic EAE by treating immunized mice with SU5416 (Semaxinib), a potent and selective inhibitor of VEGF receptor 2 (VEGFR2). Animals received seven daily injections of SU5416 (50 mg/kg) or vehicle beginning on the day after disease onset (acute study) or on day 45 post-immunization (chronic study). Spinal cord sections were collected on the day of sacrifice. Modulation of angiogenic gene expression was determined using RNA isolated from 4 acute and 4 non-immunized controls. MOG peptide induction produced extensive demyelination, immune cell infiltration, tissue laminin deposits, and axonal loss in lesions. VEGF expression was extensively increased in the acute mice, which correlated positively with clinical score. In the acute study, SU5416 treatment produced a significant clinical improvement versus vehicle controls ( p < 0.001), with less demyelination (− 37%) and cellular infiltration (− 23%) in the spinal cord ( p < 0.05). Treated animals also had significantly fewer blood vessels per section than controls (56.1 ± 6.1 v. 81.6 ± 11.5, p < 0.05), and significantly reduced laminin abnormalities (28.9% of lesion area v. 46.8%, p < 0.05). There was no improvement in clinical score or tissue pathology, and no difference in vessel number or lesion laminin expression, when SU5416 was administered during the chronic disease (all p > 0.05). In the acute study only, VEGF staining correlated with demyelination and the extent of cellular infiltration in both control ( r = 0.723, r = 0.665) and treated ( r = 0.681, r = 0.487) animals (all p < 0.05). Laminin staining in lesion areas was strongly correlated with tissue pathology for all animals in both the acute and chronic study (all p < 0.001). Vascular alterations in MOG peptide-induced EAE in the mouse are accompanied by increased lesion-specific levels of VEGF, extensive laminin deposits in the tissue and altered transcription of numerous angiogenic factors. In the microarray studies, acute mice showed a significant increase in several angiogenic RNA transcripts, six of which were verified by RT-PCR, alanyl aminopeptidase, caspase 8, Hif1a, MMP-19, plasminogen activator inhibitor, and thrombospondin1.]]></abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>19233483</pmid><doi>10.1016/j.jneuroim.2009.01.009</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0165-5728 |
ispartof | Journal of neuroimmunology, 2009-04, Vol.209 (1), p.6-15 |
issn | 0165-5728 1872-8421 |
language | eng |
recordid | cdi_proquest_miscellaneous_67145673 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Alanyl aminopeptidase Allergy and Immunology Angiogenesis Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use Angiogenic Proteins - genetics Animals Blood Vessels - drug effects Blood Vessels - metabolism Blood Vessels - pathology Caspase 8 Disease Models, Animal EAE Encephalomyelitis, Autoimmune, Experimental - drug therapy Encephalomyelitis, Autoimmune, Experimental - immunology Encephalomyelitis, Autoimmune, Experimental - metabolism Female Glycoproteins Hif1a Indoles - pharmacology Indoles - therapeutic use Laminin Laminin - drug effects Laminin - metabolism Mice Mice, Inbred C57BL MMP-19 Multiple sclerosis Myelin Sheath - drug effects Myelin Sheath - immunology Myelin Sheath - pathology Myelin-Oligodendrocyte Glycoprotein Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - metabolism Neovascularization, Pathologic - physiopathology Neurology Peptide Fragments Plasminogen activator inhibitor Pyrroles - pharmacology Pyrroles - therapeutic use Remyelination RNA, Messenger - drug effects RNA, Messenger - metabolism Spinal Cord - drug effects Spinal Cord - metabolism Spinal Cord - pathology SU5416 Thrombospondin Up-Regulation - drug effects Up-Regulation - physiology Vascular Endothelial Growth Factor A - antagonists & inhibitors Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors Vascular Endothelial Growth Factor Receptor-2 - metabolism VEGF Wallerian Degeneration - chemically induced Wallerian Degeneration - pathology Wallerian Degeneration - physiopathology |
title | VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A54%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=VEGF%20and%20angiogenesis%20in%20acute%20and%20chronic%20MOG(35%E2%80%9355)%20peptide%20induced%20EAE&rft.jtitle=Journal%20of%20neuroimmunology&rft.au=Roscoe,%20W.A&rft.date=2009-04-30&rft.volume=209&rft.issue=1&rft.spage=6&rft.epage=15&rft.pages=6-15&rft.issn=0165-5728&rft.eissn=1872-8421&rft_id=info:doi/10.1016/j.jneuroim.2009.01.009&rft_dat=%3Cproquest_cross%3E67145673%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67145673&rft_id=info:pmid/19233483&rft_els_id=1_s2_0_S0165572809000101&rfr_iscdi=true |